Zacks Research Analysts Boost Earnings Estimates for Zoetis Inc. (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Investment analysts at Zacks Research increased their Q1 2025 earnings per share estimates for Zoetis in a report issued on Wednesday, September 4th. Zacks Research analyst E. Bagri now forecasts that the company will earn $1.49 per share for the quarter, up from their previous estimate of $1.48. The consensus estimate for Zoetis’ current full-year earnings is $5.84 per share. Zacks Research also issued estimates for Zoetis’ Q2 2025 earnings at $1.66 EPS, FY2025 earnings at $6.41 EPS, Q1 2026 earnings at $1.66 EPS, Q2 2026 earnings at $1.79 EPS and FY2026 earnings at $6.98 EPS.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter last year, the company posted $1.41 EPS. The company’s quarterly revenue was up 8.3% compared to the same quarter last year.

Several other equities analysts have also recently issued reports on the company. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Stifel Nicolaus reissued a “buy” rating and set a $200.00 price target on shares of Zoetis in a research note on Tuesday, August 27th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler raised their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $217.11.

Zoetis Stock Down 0.4 %

NYSE:ZTS opened at $186.59 on Friday. The company has a market cap of $84.53 billion, a price-to-earnings ratio of 35.95, a P/E/G ratio of 2.87 and a beta of 0.88. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The stock’s fifty day moving average price is $180.90 and its two-hundred day moving average price is $174.57. Zoetis has a 52-week low of $144.80 and a 52-week high of $201.92.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ZTS. International Assets Investment Management LLC grew its holdings in shares of Zoetis by 40.7% during the fourth quarter. International Assets Investment Management LLC now owns 2,429 shares of the company’s stock worth $479,000 after buying an additional 703 shares in the last quarter. Aveo Capital Partners LLC bought a new position in Zoetis in the fourth quarter valued at $225,000. Private Advisor Group LLC increased its stake in Zoetis by 45.9% in the 4th quarter. Private Advisor Group LLC now owns 26,593 shares of the company’s stock valued at $5,249,000 after buying an additional 8,369 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in shares of Zoetis by 16.8% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 1,855 shares of the company’s stock worth $366,000 after buying an additional 267 shares during the last quarter. Finally, Gryphon Financial Partners LLC increased its position in shares of Zoetis by 11.8% in the fourth quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock valued at $601,000 after acquiring an additional 322 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.